IQ-AI Limited (GB:IQAI) has released an update.
IQ-AI Limited has experienced a significant year with new revenue records and advancements in their product development and business operations. The company is in the final stages of a phase 1 clinical trial, with preparations for a phase 2 trial underway, and is exploring funding options for this next phase. Additionally, IQ-AI is navigating regulatory pathways and leveraging recent legislative efforts to extend a rare pediatric disease program, which could benefit their future commercialization strategies.
For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.
